EMA Authorised: Duavive (oestrogens conjugated;bazedoxifene) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Duavive, a fixed-dose combination of conjugated estrogens and bazedoxifene. It is intended for use in postmenopause.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopause

Drugs mentioned

• Duavive (bazedoxifene/conjugated estrogens)

Snippet

Status: Authorised. Therapeutic area: Postmenopause. MAH: Pfizer Europe MA EEIG. Decision date: 06/11/2025